ocriplasmin

Ocriplasmin is a recombinant truncated form of human plasmin, produced using recombinant DNA technology in a Pichia pastoris expression system. It is a proteolytic enzyme with activity against protein components of the vitreous body and the vitreoretinal interface, such as laminin, fibronectin, and collagen. By cleaving these proteins, ocriplasmin dissolves the protein matrix responsible for symptomatic vitreomacular adhesion (VMA), an age-related eye condition that can lead to vision loss or blindness. Ocriplasmin is administered as a single intravitreal injection and was developed as the first pharmacological agent approved for this indication[1][2][3][4][5][7].

Brand names

Jetrea

Other names

ocriplasminmicroplasmin